Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
A Phase IB Study to Assess the Safety and Efficacy of Neoadjuvant Administration of Autologous Tumor Infiltrating Lymphocytes (LN144/Lifileucel) and Pembrolizumab for Treatment of Patients With Locally Advanced (Stage IIIB-D)/Metastatic (Stage IV) Melanoma
Sponsor: Iovance Biotherapeutics, Inc.
This PHASE1 trial investigates Locally Advanced Melanoma and Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 and is currently ongoing. Iovance Biotherapeutics, Inc. leads this study, which shows 9 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE1
-
Feb 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Nov 2022 — Apr 2024 [monthly]
Recruiting PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
May 2022 — Nov 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2022 — May 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2022 — Mar 2022 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Iovance Biotherapeutics, Inc.
- Richard Wu
For direct contact, visit the study record on ClinicalTrials.gov .